TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms

Authors
Publication date
1 January 2022
Publisher
Doi

    Abstract

    Abstract is not available.

      Similar works

      Full text

      thumbnail-image

      Available Versions

      ZORA

      redirect
      oaioai:www.zora.uzh.ch:226983
      Last time updated on 18/01/2023